Ideas to Action:

Independent research for global prosperity

Publications

 

October 22, 2020

Testimony before the USITC on COVID-19 Related Medical Supply Chains

On Wednesday, September 23, CGD Senior Fellow Prashant Yadav appeared before the United States International Trade Commission (USITC) at a virtual hearing examining “COVID-19 Related Goods: The U.S. Industry, Market, Trade, and Supply Chain Challenges.” His testimony focused on trade and supply chain issues for COVID-19 related medical products and he offered recommendations for building more resilient supply chains.

Cover of working paper 552
October 5, 2020

An Analysis of Clinical Knowledge, Absenteeism, and Availability of Resources for Maternal and Child Health: A Cross-Sectional Quality of Care Study in 10 African Countries

Our findings highlight the need to boost the knowledge of health care workers to achieve greater care readiness. Training programs have shown mixed results, so systems may need to adopt a combination of competency-based pre-service and in-service training for health care providers (with evaluation to ensure the effectiveness of the training), and hiring practices that ensure the most prepared workers enter the systems. We conclude that in settings where clinical knowledge is poor, improving drug availability or reducing health workers’ absenteeism would only modestly increase the average care readiness that meets minimum quality standards.

Laura Di Giorgio , David Evans , Magnus Lindelow , Son Nam Nguyen , Jakob Svensson , Waly Wane and Anna Welander Tärneberg
A cover image of a COVID-19 vaccine prediction paper
October 1, 2020

COVID-19 Vaccine Predictions: Using Mathematical Modelling and Expert Opinions to Estimate Timelines and Probabilities of Success of COVID-19 Vaccines

We collected publicly available information, interviewed experts, and used our diverse range of expertise to analyse and model the COVID-19 vaccine portfolio in order to generate predictions about the vaccine portfolio's timeline.

A woman being tested for coronavirus. Adobe Stock.
August 21, 2020

Using COVID-19 Test, Trace, and Isolate Systems Effectively in Middle-Income Countries

The global public health response to COVID-19 is pivoting from high-income European countries to MICs predominantly in Asia and South America. Effective test, trace, and isolate systems may be particularly valuable in MICs, where social and economic circumstances do not support large and long-term lockdowns. But investing in such systems in MICs comes with a number of limitations and opportunity costs.

July 24, 2020

Testimony on Critical US Supply Chains Amid the COVID-19 Pandemic

On July 23, 2020, CGD Senior Fellow Prashant Yadav appeared before the House Ways and Means Subcommittee on Trade at a hearing titled “Trade, Manufacturing, and Critical Supply Chains: Lessons From COVID-19.” Yadav’s testimony noted the vulnerabilities in supply chains for medical products clearly exposed by the COVID-19 pandemic and outlined key considerations for US policy toward medical supply chains moving forward.

A cover image of a whole of health look at impacts during the COVID-19 pandemic response
July 1, 2020

Beyond COVID-19: A Whole of Health Look at Impacts During the Pandemic Response

Substantial evidence has emerged relating to the potential magnitude of the indirect health effects of the coronavirus pandemic.This paper provides an overview of the lessons learned from previous outbreaks and economic crises in relation to indirect health effects as well as a framework for adopting a whole of health approach to the COVID response.

An image of a Covid-19 vaccine
June 4, 2020

India’s COVID-19 Testing Capacity Must Grow by a Factor of 10: Here’s How That Can Happen

Diagnostic testing is at the center of the policy debate around COVID-19 interventions in India. As of June 1, 2020, India had conducted approximately 3.8 million tests since it began testing in February, but many experts have noted that testing capacity is still drastically insufficient for the needs of the population.

Prashant Yadav , Abha Mehndiratta , Kalipso Chalkidou , Sidharth Rupani and Krishna Reddy
Image of MVAC vaccines process
May 7, 2020

Leave No One Behind: Using a Benefit-Based Advance Market Commitment to Incentivise Development and Global Supply of COVID-19 Vaccines

The global effort to control the COVID-19 pandemic has seen an exceptional allocation of public and philanthropic funds to advance the development of diagnostics, therapeutics, and vaccines as quickly as possible. While critical, even these significant commitments represent only a “down payment” on a price tag that could eventually exceed $50 billion just to scale the production of vaccines to control this global pandemic—amounts that cannot be raised through traditional donor and philanthropic commitments.

Pages